A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo, and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara Biocapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents), and Hartford Healthcare Endowment.

We have always walked our own path, at Alector. That’s what led us to the bold thinking and fresh, new approach of empowering the body’s immune system to fight disease. Join us in our mission to eliminate neurodegeneration and cancer through immuno-neurology and immuno-oncology. We are developing a broad portfolio of programs, currently in various stages of clinical trials. Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

Altpep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and Type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach. Our lead program aims to identify Alzheimer’s disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.

Arc is a venture-backed startup electrifying the marine industry and is headquartered in Los Angeles, California. Led by a team of former rocket engineers, we’re developing, manufacturing, and delivering high-performance electric boats at lightning speed. Our groundbreaking first model, the Arc One, set a new industry standard as the most powerful electric boat commercially available at launch. And, it was just the beginning. Our second model, the Arc Sport, is delivering electric boating to the mass market. We’re continuing to chart new waters with future models until everything that floats is electric.

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s Disease (PD) and extending across the brain and affected organs.

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve. CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models, and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people. We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry.

We build AI systems that autonomously conduct AI research. We just announced the first AI agent to autonomously create peer-reviewed literature (ICLR 2025 workshops).

Avitide, a Repligen company, discovers, develops, manufactures, and supplies custom and catalog biopharmaceutical affinity purification solutions to the biopharmaceutical industry. Avitide’s proprietary Avipure™ affinity ligand portfolio sets the standard for precise affinity separations and consistent robust performance for its high-valued chromatographic products. Avitide develops these technologies with an industry-leading 3-month concept to resin delivery service timeline that enables industry biopharmaceutical manufacturers and contract developers to achieve faster bioprocess development timelines, improved process economics, predictable scalability, and enable next-generation integrated continuous downstream processing. Avitide’s commercial resin manufacturing and supply operates under an ISO 9001:2015 quality management system and has been successfully audited for its quality systems and continuity of supply plan for its affinity chromatography products.

Hidden within our planet's vast biodiversity are solutions to some of humanity's greatest challenges, with the potential to deliver sustainable food supplies, revolutionary manufacturing capabilities, and a new generation of medicines. At Basecamp Research, we are building BaseDiscovery, a platform technology that will use next-gen DNA analysis and environmental monitoring to connect the dots and improve our understanding of the natural world. Our team uses a unique and fully portable laboratory capable of rapidly analyzing nature anywhere on Earth, discovering novel solutions to the world's most pressing challenges.

Bash helps friends arrange activities with each other. Unlike Facebook Events, group SMS, and email threads, Bash allows everybody to stay synchronized on event details. Friends who are invited receive push notifications, and events are grouped into a feed.

Bighat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. Bighat is backed by Section 32, Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors, and Gaingels.